Loading
A phase 1/2 trial of JAB-2485 (Aurora A inhibitor) in triple-negative breast cancer and small-cell lung cancer, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05490472 by Jacobio Pharmaceuticals Co., Ltd., with 102 participants planned, started 2022-12-20 and due to reach its primary completion in 2026-08. Interventions recorded: JAB-2485 (Aurora A inhibitor).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Jacobio Pharmaceuticals, Small-cell lung cancer and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Small-cell lung cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/